Cowen & Co. Maintains Their Buy Rating on Galapagos (GLPG)
In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Galapagos (GLPG). The company’s shares closed last Monday at $270.48, close to its 52-week high of $270.88.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.7% and a 52.9% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
The word on The Street in general, suggests a Hold analyst consensus rating for Galapagos with a $192.60 average price target.
See today’s analyst top recommended stocks >>
Galapagos’ market cap is currently $16.11B and has a P/E ratio of 49.12. The company has a Price to Book ratio of 5.83.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.